Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of zigakibart in adults with primary IgA nephropathy
jRCT2031260403Recruiting
- Sponsor
- Novartis
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of zigakibart in IgA nephropathy (IgAN), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of zigakibart. Started Sep 2026; status: recruiting.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2031260403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260403.